{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T19:00:07Z","timestamp":1774724407874,"version":"3.50.1"},"reference-count":106,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2005,8,1]],"date-time":"2005-08-01T00:00:00Z","timestamp":1122854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Regulatory Toxicology and Pharmacology"],"published-print":{"date-parts":[[2005,8]]},"DOI":"10.1016\/j.yrtph.2005.05.005","type":"journal-article","created":{"date-parts":[[2005,6,24]],"date-time":"2005-06-24T13:41:54Z","timestamp":1119620514000},"page":"296-312","source":"Crossref","is-referenced-by-count":355,"title":["Human pharmaceuticals in US surface waters: A human health risk assessment"],"prefix":"10.1016","volume":"42","author":[{"given":"Bradley W.","family":"Schwab","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eileen P.","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janice M.","family":"Fiori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank J.","family":"Mastrocco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas M.","family":"Roden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Cragin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger D.","family":"Meyerhoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent J.","family":"D\u2019Aco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul D.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.yrtph.2005.05.005_bib1","unstructured":"Agency for Toxic Substances and Disease Registry (ATSDR), 1996. Minimal risk levels for priority substances and guidance for derivation. Federal Register 61, 25873\u201325881."},{"key":"10.1016\/j.yrtph.2005.05.005_bib2","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1021\/es034430b","article-title":"Screening analysis of human pharmaceutical compounds in U.S. surface waters","volume":"38","author":"Anderson","year":"2004","journal-title":"Environ. Sci. Technol."},{"key":"10.1016\/j.yrtph.2005.05.005_bib3","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1016\/S0043-1354(01)00500-0","article-title":"Carbamazepine in water: persistence in the environment, ozonation treatment and preliminary assessment on algal toxicity","volume":"36","author":"Andreozzi","year":"2002","journal-title":"Water Res."},{"key":"10.1016\/j.yrtph.2005.05.005_bib4","unstructured":"American Society of Health-System Pharmacists (ASHP), 2003. AHFS Drug Information."},{"key":"10.1016\/j.yrtph.2005.05.005_bib5","doi-asserted-by":"crossref","first-page":"4377","DOI":"10.1021\/jm960073m","article-title":"Octanol-chloroform- and propylene glycol dipelargonat-water partitioning of morphine-6-glucuronide and other related opiates","volume":"39","author":"Avdeef","year":"1996","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.yrtph.2005.05.005_bib6","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/jps.2600820214","article-title":"pH-metric log P. II: refinement of partition coefficients and ionization constants of multiprotic substances","volume":"82","author":"Avdeef","year":"1993","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.yrtph.2005.05.005_bib7","series-title":"Goodman & Gilman\u2019s The Pharmacological Basis of Therapeutics","first-page":"5","article-title":"Pharmacokinetics: the dynamics of drug absorption, distribution and elimination","author":"Benet","year":"1996"},{"key":"10.1016\/j.yrtph.2005.05.005_bib8","unstructured":"Bern, M., Bierbaum, B., Wetzner, S., 1997. Fixed very low dose vs. variable dose warfarin for deep vein thrombosis (DVT) prophylaxis. Thromb. and Haemost. 0 (Suppl.), 330PS."},{"issue":"1\u20133","key":"10.1016\/j.yrtph.2005.05.005_bib9","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0048-9697(03)00138-4","article-title":"Pharmaceuticals and personal care products (PPCPs) in surface and treated waters of Louisiana, USA and Ontario, Canada","volume":"311","author":"Boyd","year":"2003","journal-title":"Sci. Total Environ."},{"key":"10.1016\/j.yrtph.2005.05.005_bib10","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1021\/bk-2003-0850.ch012","article-title":"The determination and quantification of human pharmaceuticals in aqueous environmental samples","volume":"850","author":"Bratton","year":"2003","journal-title":"ACS Symp. Ser."},{"key":"10.1016\/j.yrtph.2005.05.005_bib11","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1021\/es981014w","article-title":"Occurrence and environmental behavior of the chiral pharmaceutical drug ibuprofen in surface waters and in wastewater","volume":"33","author":"Buser","year":"1999","journal-title":"Environ. Sci. Technol."},{"issue":"7","key":"10.1016\/j.yrtph.2005.05.005_bib12","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1021\/es020158e","article-title":"Strategic survey of therapeutic drugs in the rivers Po and Lambro in northern Italy","volume":"37","author":"Calamari","year":"2003","journal-title":"Environ. Sci. Technol."},{"key":"10.1016\/j.yrtph.2005.05.005_bib13","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1006\/rtph.1998.1253","article-title":"Pharmaceuticals in the environment\u2014a human risk?","volume":"28","author":"Christensen","year":"1998","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2005.05.005_bib14","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1021\/es035119x","article-title":"Environmental risk assessment of paroxetine","volume":"38","author":"Cunningham","year":"2004","journal-title":"Environ. Sci. Technol."},{"key":"10.1016\/j.yrtph.2005.05.005_bib15","series-title":"Pharmaceuticals in the environment: sources, fate, effects and risks","first-page":"13","article-title":"Special characteristics of pharmaceuticals related to environmental fate","author":"Cunningham","year":"2004"},{"key":"10.1016\/j.yrtph.2005.05.005_bib16","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1006\/rtph.1996.0116","article-title":"Evolution of science-based uncertainty factors in non-cancer risk assessment","volume":"24","author":"Dourson","year":"1996","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2005.05.005_bib17","unstructured":"Eli Lilly and Company, 2000. Fluoxetine Hydrochloride Capsules and Tablets. Material Safety Data Sheet."},{"key":"10.1016\/j.yrtph.2005.05.005_bib18","unstructured":"European Agency for the Evaluation of Medicinal Products (EMEA), 1997. The European agency for the evaluation of medicinal products veterinary medicines evaluation unit. Maximum Residue Limits. Trimethoprim. Summary report (2). EMEA\/MRL\/255\/97-Final."},{"key":"10.1016\/j.yrtph.2005.05.005_bib19","unstructured":"European Agency for the Evaluation of Medicinal Products (EMEA), 1998. Maximum Residue Limit. Enrofloxacin. Summary report (2). EMEA\/MRL\/388\/98-Final."},{"issue":"1\u20132","key":"10.1016\/j.yrtph.2005.05.005_bib20","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0021-9673(01)01154-2","article-title":"Determination of drugs in surface water and wastewater samples by liquid chromatography-mass spectrometry: methods and preliminary results including toxicity studies with Vibrio fischeri","volume":"938","author":"Farre","year":"2001","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.yrtph.2005.05.005_bib21","unstructured":"Goodman & Gilman\u2019s The Pharmacological Basis of Therapeutics. 2001. tenth ed., J.G. Hardman, L.E. Limbird (Eds.), McGraw-Hill, Elmsford."},{"key":"10.1016\/j.yrtph.2005.05.005_bib22","unstructured":"Goodman & Gilman\u2019s The Pharmacological Basis of Therapeutics. 2005. McGraw-Hill, Elmsford, NY, online version accessed 19 March 2005."},{"issue":"9","key":"10.1016\/j.yrtph.2005.05.005_bib23","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1897\/03-606","article-title":"Occurrence and fate of pharmaceuticals and alkylphenol ethoxylate metabolites in an effluent-dominated river and wetland","volume":"23","author":"Gross","year":"2004","journal-title":"Environ. Toxicol. Chem."},{"key":"10.1016\/j.yrtph.2005.05.005_bib24","unstructured":"GSK, 2002. Tagamet, Prescribing Information, TG:L93, GlaxoSmithKline, Research Triangle Park, NC, June 2002."},{"key":"10.1016\/j.yrtph.2005.05.005_bib25","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0045-6535(97)00354-8","article-title":"Occurrence, fate and effects of pharmaceutical substances in the environment\u2014a review","volume":"36","author":"Halling-Sorensen","year":"1998","journal-title":"Chemosphere"},{"key":"10.1016\/j.yrtph.2005.05.005_bib26","unstructured":"Hansch, C., Leo, A., Hoekman, D., 1995. Exploring QSAR. Hydrophobic, electronic, and steric constants. ACS Professional Reference Book. American Chemical Society, Washington, DC."},{"key":"10.1016\/j.yrtph.2005.05.005_bib27","unstructured":"Hartig, C., Jekel, M., 2001. Occurrence of bacteriostatic sulfonamide drugs in surface waters and their behavior in bank filtration. NGWA, 2nd International Conference on Pharmaceuticals and Endocrine Disrupting Chemicals in Water, October 9\u201311, 2001."},{"key":"10.1016\/j.yrtph.2005.05.005_bib28","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0021-9673(99)00378-7","article-title":"Detection and identification of sulphonamide drugs in municipal waste water by liquid chromatography coupled with electrospray ionisation tandem mass spectrometry","volume":"854","author":"Hartig","year":"1999","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.yrtph.2005.05.005_bib29","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0378-4274(02)00041-3","article-title":"Occurrence, fate, and removal of pharmaceutical residues in the aquatic environment: a review of recent research data","volume":"131","author":"Heberer","year":"2002","journal-title":"Toxicol. Lett."},{"issue":"3","key":"10.1016\/j.yrtph.2005.05.005_bib30","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2166\/wst.2002.0060","article-title":"From municipal sewage to drinking water: fate and removal of pharmaceutical residues in the aquatic environment in urban areas","volume":"46","author":"Heberer","year":"2002","journal-title":"Water Sci. Technol."},{"issue":"1\u20132","key":"10.1016\/j.yrtph.2005.05.005_bib31","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0021-9673(03)01213-5","article-title":"Determination of selected human pharmaceutical compounds in effluent and surface water samples by high-performance liquid chromatography-electrospray tandem mass spectrometry","volume":"1015","author":"Hilton","year":"2003","journal-title":"J. Chromatogr. A (Netherlands)"},{"key":"10.1016\/j.yrtph.2005.05.005_bib32","first-page":"263","article-title":"Determination of beta-blockers and B2-sympatomimetics in the aquatic environment","volume":"87","author":"Hirsch","year":"1996","journal-title":"Vom Wasser"},{"key":"10.1016\/j.yrtph.2005.05.005_bib33","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0048-9697(98)00337-4","article-title":"Occurrence of antibiotics in the aquatic environment","volume":"225","author":"Hirsch","year":"1999","journal-title":"Sci. Total Environ."},{"key":"10.1016\/j.yrtph.2005.05.005_bib34","unstructured":"Hoechst, 1999. Cardizem\u00ae (diltiazem HCl), Pescribing Information, Hoechst Marion Roussel, Kansas City, MO, May 1999."},{"key":"10.1016\/j.yrtph.2005.05.005_bib35","unstructured":"Hoffman, B.F., Bigger, J.T., 1990. Digitalis and allied cardiac glycosides. In: Gilman, A.G., Rall, T., Nies, A., Taylor, P. (Eds.), Goodman & Gilman\u2019s The Pharmacological Basis of Therapeutics, eighth ed., p. 814."},{"key":"10.1016\/j.yrtph.2005.05.005_bib36","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1021\/es025896h","article-title":"Oxidation of pharmaceuticals during ozonation and advanced oxidation processes","volume":"37","author":"Huber","year":"2003","journal-title":"Environ. Sci. Technol."},{"key":"10.1016\/j.yrtph.2005.05.005_bib37","unstructured":"Hazardous Substances Data Bank (HSDB), 2005. National Library of Medicine, http:\/\/toxnet.nlm.nih.gov\/, accessed 31 March 2005."},{"key":"10.1016\/j.yrtph.2005.05.005_bib38","unstructured":"IMS Health Inc., 2003. National Sales PerspectivesTM, January 2003."},{"key":"10.1016\/j.yrtph.2005.05.005_bib39","unstructured":"International Programme on Chemical Safety (IPCS), 1994. Assessing human health risk of chemicals: the derivation of guidance values for health-based exposure limits. Environmental Health Criteria No. 170, Geneva."},{"key":"10.1016\/j.yrtph.2005.05.005_bib40","unstructured":"International Programme on Chemical Safety (IPCS), 2001. Guidance document for the use of data in development of chemical-specific adjustment factors (CSAF) for interspecies differences and human variability in dose\/concentration response assessment. WHO\/PCS\/01.4."},{"key":"10.1016\/j.yrtph.2005.05.005_bib41","unstructured":"Joint FAO\/WHO Expert Committee on Food Additives (JECFA), 1994. Toxicological evaluation of certain veterinary drug residues in food. Sulfadimidine. WHO Food Additives Series, No. 33. World Health Organization, Geneva."},{"key":"10.1016\/j.yrtph.2005.05.005_bib42","unstructured":"Joint FAO\/WHO Expert Committee on Food Additives (JECFA), 1998. Toxicological evaluation of certain veterinary drug residues in food. Tetracyclines: oxytetracycline, chlortetracycline, and tetracycline (addendum). WHO Food Additive Series 41. World Health Organization, Geneva."},{"key":"10.1016\/j.yrtph.2005.05.005_bib43","unstructured":"Joint FAO\/WHO Expert Committee on Food Additives (JECFA), 2000. Toxicological evaluation of certain veterinary drug residues in food. Lincomycin. WHO Food Additive Series 45. World Health Organization, Geneva."},{"key":"10.1016\/j.yrtph.2005.05.005_bib44","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1078\/1438-4639-00166","article-title":"Detection of pharmaceutical contaminations of river, pond, and tap water from Cologne (Germany) and surroundings","volume":"205","author":"Jux","year":"2002","journal-title":"Int. J. Hyg. Environ. Health"},{"key":"10.1016\/j.yrtph.2005.05.005_bib45","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1021\/es011055j","article-title":"Pharmaceuticals, hormones, and other organic wastewater contaminants in U.S. streams, 1999\u20132000: a national reconnaissance","volume":"36","author":"Kolpin","year":"2002","journal-title":"Environ. Sci. Technol."},{"issue":"1\u20133","key":"10.1016\/j.yrtph.2005.05.005_bib46","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.scitotenv.2004.01.015","article-title":"Urban contribution of pharmaceuticals and other organic wastewater contaminants to streams during differing flow conditions","volume":"328","author":"Kolpin","year":"2004","journal-title":"Sci. Total Environ."},{"key":"10.1016\/j.yrtph.2005.05.005_bib47","first-page":"33","article-title":"100-fold margin of safety","volume":"18","author":"Lehman","year":"1954","journal-title":"Assoc. Food Drug Off. U.S.Q. Bull."},{"issue":"19","key":"10.1016\/j.yrtph.2005.05.005_bib48","doi-asserted-by":"crossref","first-page":"4640","DOI":"10.1021\/ac010514w","article-title":"Analysis of trace levels of sulfonamide and tetracycline antimicrobials in groundwater and surface water using solid-phase extraction and liquid chromatography\/mass spectrometry","volume":"73","author":"Lindsey","year":"2001","journal-title":"Anal. Chem."},{"issue":"3","key":"10.1016\/j.yrtph.2005.05.005_bib49","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1039\/b300440f","article-title":"Multi-component analysis of polar water pollutants using sequential solid-phase extraction followed by LC-ESI-MS","volume":"5","author":"Loos","year":"2003","journal-title":"J. Environ. Monit. (United Kingdom)"},{"key":"10.1016\/j.yrtph.2005.05.005_bib50","unstructured":"Martindale, 2005. Cimetidine, in Martindale\u2014the complete drug reference\u2014monographs, 1982\u20132005. The Pharmaceutical Press, accessed 30 March 2005."},{"key":"10.1016\/j.yrtph.2005.05.005_bib51","doi-asserted-by":"crossref","unstructured":"McClung, M.R., Geusens, P., Miller, P.D., Zippel, H., Bensen, W.G., Roux, C., Adami, S., Fogelman, I., Diamond, T., Eastell, R., Meunier, P.J., Reginster, J., for The Hip Intervention Program Study Group, 2001. Effect of risedronate on the risk of hip fracture in elderly women. New Engl. J. Med. 344, 333\u2013340.","DOI":"10.1056\/NEJM200102013440503"},{"key":"10.1016\/j.yrtph.2005.05.005_bib52","unstructured":"Merck, 2004. NOROXIN\u00ae (norfloxacin, MSD), International Physician Circular, IPC-NRX-T-042004, Merck & Co., Whitehouse Station, NJ, 12 April 2004."},{"key":"10.1016\/j.yrtph.2005.05.005_bib53","unstructured":"Merck 2005. RENITEC\u00ae, Oral Tablet (enalapril maleate, MSD), Injection (enalaprilat, MSD), International Physician Circular, IPC-RNT-MF-032005, Merck & Co., Whitehouse Station, NJ, 29 March 2005."},{"key":"10.1016\/j.yrtph.2005.05.005_bib54","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/etc.5620180412","article-title":"Improved method for estimating bioconcentration\/bioaccumulation factor from octanol\/water partition coefficient","volume":"18","author":"Meylan","year":"1999","journal-title":"Environ. Toxicol. Chem."},{"issue":"5\u20136","key":"10.1016\/j.yrtph.2005.05.005_bib55","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1365\/s10337-003-0052-4","article-title":"Determination of non-steroidal anti-inflammatory drugs in surface water and wastewater by liquid chromatography-tandem mass spectrometry","volume":"58","author":"Marchese","year":"2003","journal-title":"Chromatographia"},{"key":"10.1016\/j.yrtph.2005.05.005_bib56","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1021\/jm960436i","article-title":"Quantitative structure-activity relationships among macrolide antibacterial agents: in vitro and in vivo potency against Pasteurella multocida","volume":"40","author":"McFarland","year":"1997","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.yrtph.2005.05.005_bib57","unstructured":"McQuillan, D., Parker, J., Chapman, T.H., Sherrell, K., Mills, D., 2001. Drug residues in ambient water: initial surveillance in New Mexico, USA. NGWA, 2nd International Conference on Pharmaceuticals and Endocrine Disrupting Chemicals in Water, October 9\u201311, 2001."},{"issue":"12","key":"10.1016\/j.yrtph.2005.05.005_bib58","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1897\/02-627","article-title":"Distribution of acidic and neutral drugs in surface waters near sewage treatment plants in the lower Great Lakes, Canada","volume":"22","author":"Metcalfe","year":"2003","journal-title":"Environ. Toxicol. Chem."},{"key":"10.1016\/j.yrtph.2005.05.005_bib59","unstructured":"Mons, M.N., Hoogenboom, A.C., Noij, T.H.M., 2003. Pharmaceuticals and drinking water supply in the Netherlands. BTO 2003.040, Kiwa N.V. Water Research. Nieuwegein, The Netherlands."},{"issue":"5","key":"10.1016\/j.yrtph.2005.05.005_bib60","first-page":"31","article-title":"When the cure is the problem: antibiotic contamination of surface water and groundwater may be promoting the development of drug resistant pathogens","volume":"13","author":"Mulroy","year":"2001","journal-title":"Water Environ. Technol."},{"key":"10.1016\/j.yrtph.2005.05.005_bib61","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1080\/10807039509380049","article-title":"Scientific basis for uncertainty factors used to establish occupational exposure limits for pharmaceutical active ingredients","volume":"1","author":"Naumann","year":"1995","journal-title":"Hum. Ecol. Risk Assess."},{"key":"10.1016\/j.yrtph.2005.05.005_bib62","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in post-menopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.yrtph.2005.05.005_bib63","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0021-9673(01)00514-3","article-title":"Simultaneous quantification of neutral and acidic pharmaceuticals and pesticides at the low-ng\/L level in surface and waste water","volume":"911","author":"Ollers","year":"2001","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.yrtph.2005.05.005_bib64","unstructured":"Physicians\u2019 Desk Reference (PDR), 2005a. Main Edition. Published by Thompson Healthcare, Montvale, NJ, online version accessed 29 March 2005."},{"key":"10.1016\/j.yrtph.2005.05.005_bib65","unstructured":"Physicians\u2019 Desk Reference (PDR), 2005b. Main Edition. Published by Thompson Healthcare, Montvale, NJ, online version accessed 31 March 2005."},{"key":"10.1016\/j.yrtph.2005.05.005_bib66","unstructured":"Physicians\u2019 Desk Reference (PDR), 2005c. Main Edition. Published by Thompson Healthcare, Montvale, NJ, online version accessed 06 April 2005."},{"key":"10.1016\/j.yrtph.2005.05.005_bib67","unstructured":"Pfizer, 2003. LOPID\u00ae (Gemfibrozil, USP). Tablets Package Insert, Parke-Davis, Division of Pfizer Inc., NY, October 2003."},{"key":"10.1016\/j.yrtph.2005.05.005_bib68","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1056\/NEJM199810083391503","article-title":"Effect of nebulized ipratropium on the hospitalization rates of children with asthma","volume":"339","author":"Qureshi","year":"1998","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.yrtph.2005.05.005_bib69","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1080\/02652039309374152","article-title":"Data-derived safety factors for the evaluation of food additives and environmental contaminants","volume":"10","author":"Renwick","year":"1993","journal-title":"Food Addit. Contam."},{"key":"10.1016\/j.yrtph.2005.05.005_bib70","series-title":"Struktur-Bioreaktivitat-WirkungsbezogeneEigenschaften Eigenschaften","author":"Roth","year":"1994"},{"key":"10.1016\/j.yrtph.2005.05.005_bib71","series-title":"LOGKOW Databank. A databank of evaluated octanol-water partition coefficients (Log P) on microcomputer diskette","author":"Sangster","year":"1994"},{"key":"10.1016\/j.yrtph.2005.05.005_bib72","first-page":"233","article-title":"Occurrence of drugs in surface waters","volume":"90","author":"Sacher","year":"1998","journal-title":"Vom Wasser"},{"key":"10.1016\/j.yrtph.2005.05.005_bib73","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1080\/10807030290879899","article-title":"A human health risk assessment of pharmaceuticals in the aquatic environment","volume":"8","author":"Schulman","year":"2002","journal-title":"Hum. Ecol. Risk Assess."},{"key":"10.1016\/j.yrtph.2005.05.005_bib74","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1080\/10807039991289347","article-title":"Establishing data-derived adjustment factors from published pharmaceutical clinical trial data","volume":"5","author":"Silverman","year":"1999","journal-title":"Hum. Ecol. Risk Assess."},{"key":"10.1016\/j.yrtph.2005.05.005_bib75","doi-asserted-by":"crossref","unstructured":"Snyder, S.A., Kelly, K.L., Grange, A.H., Sovocool, G.W., Snyder, E.M., Giesy, J.P., 2001. Pharmaceuticals and Personal Care Products in the Waters of Lake Mead, Nevada. Pharmaceuticals and Personal Care Products in the Environment, ACS Symposium Series 791, Oxford University Press, 116\u2013141.","DOI":"10.1021\/bk-2001-0791.ch007"},{"key":"10.1016\/j.yrtph.2005.05.005_bib76","doi-asserted-by":"crossref","unstructured":"SOLVD Investigators, 1991. Effects of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. New Engl. J. Med. 325, 293\u2013302.","DOI":"10.1056\/NEJM199108013250501"},{"issue":"7","key":"10.1016\/j.yrtph.2005.05.005_bib77","first-page":"M20","article-title":"Pharmaceuticals in the aquatic environment","volume":"25","author":"Stan","year":"1997","journal-title":"Analusis Mag."},{"key":"10.1016\/j.yrtph.2005.05.005_bib78","first-page":"291","article-title":"Determination of drugs in sewage treatment plants and river water","volume":"86","author":"Stumpf","year":"1996","journal-title":"Vom Wasser"},{"key":"10.1016\/j.yrtph.2005.05.005_bib79","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0048-9697(98)00339-8","article-title":"Polar drug residues in sewage and natural waters in the state of Rio de Janeiro, Brazil","volume":"225","author":"Stumpf","year":"1999","journal-title":"Sci. Total Environ."},{"key":"10.1016\/j.yrtph.2005.05.005_bib80","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/0041-008X(73)90041-0","article-title":"Observations on the thyroid gland in rats following the administration of sulfamethoxazole and trimethoprim","volume":"24","author":"Swarm","year":"1973","journal-title":"Appl. Pharmacol."},{"issue":"2\u20133","key":"10.1016\/j.yrtph.2005.05.005_bib81","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0378-5173(92)90099-N","article-title":"Lipophilicity antibacterial fluoroquinolones","volume":"79","author":"Takacs-Novak","year":"1992","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.yrtph.2005.05.005_bib82","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1016\/S0043-1354(98)00099-2","article-title":"Occurrence of drugs in German sewage treatment plants and rivers","volume":"32","author":"Ternes","year":"1998","journal-title":"Water Res."},{"key":"10.1016\/j.yrtph.2005.05.005_bib83","doi-asserted-by":"crossref","unstructured":"Ternes, T., 2001. Pharmaceuticals and metabolites as contaminants of the aquatic environment. In: Daughton, C.G., Jones-Lepp, T.L. (Eds.), Pharmaceutical and Personal Care Products in the Environment: Scientific and Regulatory. American Chemical Society, Washington, DC, pp. 39\u201354.","DOI":"10.1021\/bk-2001-0791.ch002"},{"key":"10.1016\/j.yrtph.2005.05.005_bib84","doi-asserted-by":"crossref","first-page":"3855","DOI":"10.1021\/es015757k","article-title":"Removal of pharmaceuticals during drinking water treatment","volume":"36","author":"Ternes","year":"2002","journal-title":"Environ. Sci. Technol."},{"issue":"6","key":"10.1016\/j.yrtph.2005.05.005_bib85","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1021\/es025834r","article-title":"Occurrence and fate of carbamazepine, clofibric acid, diclofenac, ibuprofen, ketoprofen, and naproxen in surface waters","volume":"37","author":"Tixier","year":"2002","journal-title":"Environ. Sci. Technol."},{"key":"10.1016\/j.yrtph.2005.05.005_bib86","unstructured":"U.S. Census Bureau, 2004. Population and Ranking Tables of the Older Population for the United States, States, Puerto Rico, Places of 100,000 or More Population, and Counties (PHC\u2013T\u201313), http:\/\/www.census.gov\/population\/www\/cen2000\/phc-t13.html, accessed 02 May 2004."},{"key":"10.1016\/j.yrtph.2005.05.005_bib87","unstructured":"U.S. EPA, 1989. Risk Assessment Guidance for Superfund, vol. I. Human Health Evaluation Manual. EPA\/540\/1-89\/002, December 1989."},{"key":"10.1016\/j.yrtph.2005.05.005_bib88","unstructured":"U.S. EPA, 2000. Methodology for deriving ambient water quality criteria for the protection of human health. Office of Water, Office of Science and Technology. EPA-822-B-00-004, October 2000."},{"key":"10.1016\/j.yrtph.2005.05.005_bib89","unstructured":"U.S. EPA, 2002. A review of the reference dose and reference concentration processes. EPA\/630\/P-02\/002F, p. 192."},{"key":"10.1016\/j.yrtph.2005.05.005_bib90","unstructured":"U.S. FDA, 1997. 21CFR Part 25.20-31. Actions requiring preparation of an environmental assessment and categorical exclusions."},{"key":"10.1016\/j.yrtph.2005.05.005_bib91","unstructured":"U.S. FDA, 1998. Guidance for industry: environmental assessment of human drug and biologics applications. Revision 1. p. 42 (www.fda.gov\/cder\/guidance\/1730fnl.pdf)."},{"key":"10.1016\/j.yrtph.2005.05.005_bib92","unstructured":"U.S. FDA, 1999. Benefit vs. Risk: how CDER approves new drugs. In: From test tube to patient: improving health through human drugs. U.S. Food and Drug Administration Center for Drug Evaluation and Research Special Report. pp. 33\u201340 (www.fda.gov\/cder\/about\/whatwedo\/testtube-full.pdf)."},{"issue":"22","key":"10.1016\/j.yrtph.2005.05.005_bib93","doi-asserted-by":"crossref","first-page":"6265","DOI":"10.1021\/ac034210g","article-title":"Analysis of endocrine disruptors, pharmaceuticals, and personal care products in water using liquid chromatography\/tandem mass spectrometry","volume":"75","author":"Vanderford","year":"2003","journal-title":"Anal. Chem."},{"key":"10.1016\/j.yrtph.2005.05.005_bib94","doi-asserted-by":"crossref","unstructured":"Watts, C.D., Crathorne, B., Fielding, M., Steel, C.P., 1983. Identification of non-volatile organics in water using field desorption mass spectrometry and high performance liquid chromatography. Presented at the 3rd European Symposium on Organic Micropollutants in water, Oslo, Norway, September 19\u201321. In: Angeletti, G., Bj\u00f8rseth, A. (Eds.), Analysis of Organic Micropollutants in Water. DD Reidel Publishing Co., Dordrecht. pp. 120\u2013131.","DOI":"10.1007\/978-94-009-6345-0_13"},{"key":"10.1016\/j.yrtph.2005.05.005_bib95","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0378-4274(03)00071-7","article-title":"Indirect exposure to pharmaceuticals via drinking water","volume":"142","author":"Webb","year":"2003","journal-title":"Toxicol. Lett."},{"issue":"1\u20133","key":"10.1016\/j.yrtph.2005.05.005_bib96","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0048-9697(02)00064-5","article-title":"Drugs and personal care products as ubiquitous pollutants: occurrence and distribution of clofibric acid, caffeine and DEET in the North Sea","volume":"295","author":"Weigel","year":"2002","journal-title":"Sci. Total Environ."},{"issue":"6","key":"10.1016\/j.yrtph.2005.05.005_bib97","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.chemosphere.2004.04.015","article-title":"Determination of selected pharmaceuticals and caffeine in sewage and seawater from Tromso\/Norway with emphasis on ibuprofen and its metabolites","volume":"56","author":"Weigel","year":"2004","journal-title":"Chemosphere"},{"issue":"2","key":"10.1016\/j.yrtph.2005.05.005_bib98","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.chroma.2003.10.036","article-title":"Simultaneous solid-phase extraction of acidic, neutral and basic pharmaceuticals from aqueous samples at ambient (neutral) pH and their determination by gas chromatography-mass spectrometry","volume":"1023","author":"Weigel","year":"2004","journal-title":"J. Chromatogr. A"},{"issue":"2","key":"10.1016\/j.yrtph.2005.05.005_bib99","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.chemosphere.2004.05.017","article-title":"Pharmaceuticals in the river Elbe and its tributaries","volume":"57","author":"Weigel","year":"2004","journal-title":"Chemosphere"},{"key":"10.1016\/j.yrtph.2005.05.005_bib100","unstructured":"Williams, R.T., 2005. Human health pharmaceuticals in the environment: An introduction. In: Williams, R.T. (Ed.), Science for Assessing the Impacts of Human Pharmaceuticals on Aquatic Ecosystems. Society of Environmental Toxicology and Chemistry (SETAC), Pensacola, FL, forthcoming."},{"issue":"13","key":"10.1016\/j.yrtph.2005.05.005_bib101","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1016\/S0043-1354(01)00026-4","article-title":"Selective degradation of ibuprofen and clofibric acid in two model river biofilm systems","volume":"35","author":"Winkler","year":"2001","journal-title":"Water Res."},{"issue":"19","key":"10.1016\/j.yrtph.2005.05.005_bib102","doi-asserted-by":"crossref","first-page":"4645","DOI":"10.1016\/S0043-1354(03)00399-3","article-title":"Evolution of antibiotic occurrence in a river through pristine, urban and agricultural landscapes","volume":"37","author":"Yang","year":"2003","journal-title":"Water Res. (United Kingdom)"},{"issue":"14\u201315","key":"10.1016\/j.yrtph.2005.05.005_bib103","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1016\/j.watres.2004.04.028","article-title":"Routine monitoring of antibiotics in water and wastewater with a radioimmunoassay technique","volume":"38","author":"Yang","year":"2004","journal-title":"Water Res."},{"issue":"1\u20132","key":"10.1016\/j.yrtph.2005.05.005_bib104","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.chroma.2004.02.084","article-title":"Solid-phase extraction-high-performance liquid chromatography-ion trap mass spectrometry for analysis of trace concentrations of macrolide antibiotics in natural and waste water matrices","volume":"1038","author":"Yang","year":"2004","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.yrtph.2005.05.005_bib105","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1093\/qjmed\/89.2.127","article-title":"Factors determining the maintenance dose of warfarin in Chinese patients","volume":"89","author":"Yu","year":"1996","journal-title":"Q. J. Med."},{"key":"10.1016\/j.yrtph.2005.05.005_bib106","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/S0140-6736(00)02270-4","article-title":"Presence of therapeutic drugs in the environment","volume":"355","author":"Zuccato","year":"2000","journal-title":"Lancet"}],"container-title":["Regulatory Toxicology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230005000759?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230005000759?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T13:40:15Z","timestamp":1683121215000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0273230005000759"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8]]},"references-count":106,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,8]]}},"alternative-id":["S0273230005000759"],"URL":"https:\/\/doi.org\/10.1016\/j.yrtph.2005.05.005","relation":{},"ISSN":["0273-2300"],"issn-type":[{"value":"0273-2300","type":"print"}],"subject":[],"published":{"date-parts":[[2005,8]]}}}